Literature DB >> 18678282

Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine.

Paul Workman, Johann de Bono.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18678282     DOI： 10.1016/j.coph.2008.07.007

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


× No keyword cloud information.
  14 in total

Review 1.  Envisioning the future of early anticancer drug development.

Authors:  Timothy A Yap; Shahneen K Sandhu; Paul Workman; Johann S de Bono
Journal:  Nat Rev Cancer       Date:  2010-06-10       Impact factor: 60.716

2.  Cancer: Exploiting collateral damage.

Authors:  Ben Lehner; Solip Park
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

Review 3.  Cancer research: past, present and future.

Authors:  Ya Cao; Ronald A DePinho; Matthias Ernst; Karen Vousden
Journal:  Nat Rev Cancer       Date:  2011-09-15       Impact factor: 60.716

Review 4.  SIRT3 and cancer: tumor promoter or suppressor?

Authors:  Turki Y Alhazzazi; Pachiyappan Kamarajan; Eric Verdin; Yvonne L Kapila
Journal:  Biochim Biophys Acta       Date:  2011-05-07

5.  Translating cancer research into targeted therapeutics.

Authors:  J S de Bono; Alan Ashworth
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962

Review 6.  Genomic markers for decision making: what is preventing us from using markers?

Authors:  Vicky M Coyle; Patrick G Johnston
Journal:  Nat Rev Clin Oncol       Date:  2009-12-15       Impact factor: 66.675

7.  Gene expression profiling of taxol-resistant nasopharyngeal carcinoma cells with siRNA-mediated FOLR1 downregulation.

Authors:  Yexun Song; Xiaowei Peng; Min Wang; Jun Xie; Guolin Tan
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

9.  Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.

Authors:  C Montagut; M Iglesias; M Arumi; B Bellosillo; M Gallen; A Martinez-Fernandez; L Martinez-Aviles; I Cañadas; A Dalmases; E Moragon; L Lema; S Serrano; A Rovira; F Rojo; J Bellmunt; J Albanell
Journal:  Br J Cancer       Date:  2010-03-16       Impact factor: 7.640

10.  Digital holographic microscopy for non-invasive monitoring of cell cycle arrest in L929 cells.

Authors:  Maria Falck Miniotis; Anthonny Mukwaya; Anette Gjörloff Wingren
Journal:  PLoS One       Date:  2014-09-10       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.